we're reaching the point where AI is emailing AI

Pleased to be a guest on Business Trip again, this time to discuss FDA's MDMA AdComm and its potential broader implications for the field. businesstrip.fm/podcast/episod…

future founders: do you have a startup idea in brain and mental health that you’ve been bouncing around and want feedback on? I’m offering an office hour session this Friday 2pm est (on Zoom). DM me for a 10 min slot. No ideas are too early!

Announcing our investment in Ancilia Biosciences, a biotech working on next-gen microbial therapeutics harnessing the power of CRISPR. The microbiome’s impact on human health is undeniable, but many treatments have challenges in effectiveness. Ancilia’s key insight: bacterial

New episode: environmental toxins and mental health w/ Gurdane Bhutani of MBX Capital (link to episode below)

this is a great ethics pledge for VCs: govclab.com/2024/02/12/men…. I support it!

New podcast episode! Navigating FDA clinical trials in Neurotech w/ Tim Marjenin. Tim is Head of Neurology Regulatory Affairs at MCRA (previously 16 years at FDA). If you're building in the neurotech, this episode is packed with tips. - FDA's approach to novel

I got into breathwork by going to in-person classes. With some practice, I can now do it from home with an app and basically the same amount of benefit. IRL first, URL later. I don’t think this would work the other way around. Makes me re-think apps that are virtual only vs.

Announcing our investment in Sanmai Technologies: transcranial focused ultrasound (tFUS) to treat mental health conditions. tFUS as a technology is mindblowing. It's versatile, powerful, and precise. It's hard not to see it playing a huge role in the future of mental health! We

ask chat GPT to scrape everything it knows about you and describe you in the tone of Jack Kerouac

Excited to have KV and Psymed supporting our journey! Our beta is currently open to new users—join our waitlist on our website to try Neurode. As someone diagnosed with ADHD at the age of 5, we are building the product I wish I had. Read more below:

Announcing neurode private beta and their pre-seed round by PsyMed Ventures and Khosla Ventures We need and can do better than offering amphetamines as the standard of care for ADHD. Even bigger than that, the potential of low-cost, high-quality brain images and